Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 35515 clinical trials
Featured trial
Alzheimer's Disease and Precision Medicine Research Among Native People

video-based materials for recruitment into AD and PM research, and by creating an AD-PM registry of AI/AN individuals who are willing to be contacted for future research opportunities.

Accepts healthy volunteers
  • 04 Oct, 2022
  • 1 location
Featured trial
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

clinical study might be a suitable option for you. To qualify for this study, you must:·    &nbsp

mini-mental state examination
mental state examination
mild cognitive impairment
cognitive impairment
  • 22 Sep, 2022
  • 86 locations
Featured trial
Study to evaluate HZN-825 in patients with Idiopathic Pulmonary Fibrosis (IPF)

daily (QD) or twice daily (BID)) or a placebo regimen for 52 weeks. Participants who complete the duration of this trial may be eligible to enter an open-label 52-week extension trial where all patients

diffusion capacity of the lung for carbon monoxide
  • 18 Oct, 2022
  • 53 locations
Featured trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension (HIMALAYA)  

24 week, double blind, placebo controlled part, preceded by a screening period of up to 4 weeks before Day 1. On Day 1 of Part A, participants will be randomized in a 2:1 ratio to the

primary lateral sclerosis
body mass index
  • 08 Nov, 2022
  • 44 locations
Featured trial
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY) (PATHWAY)

The purpose of this study is to evaluate the efficacy and safety of parsaclisib compared with placebo in participants with Primary Warm Autoimmune Hemolytic Anemia (wAIHA),

  • 11 Nov, 2022
  • 39 locations
Featured trial
A Trial Evaluating Different Dosing Durations of TEPEZZA® Treatment in Patients with Thyroid Eye Disease (TED)

The overall objective is to investigate the safety, tolerability and need for re-treatment of 3 different TEPEZZA® treatment durations (4, 8, or 16 infusions) in patients with TED.

  • 13 Oct, 2022
  • 14 locations
Featured trial
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety …

disease or disorder
oligoclonal bands
  • 09 Nov, 2022
  • 11 locations
Featured trial
The Orchestra Study: An 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

The Orchestra Study (study number PD0053) is a clinical research study for people with early-stage Parkinson’s disease (<2 years). The aim of the study is to find out whether an investigational medication known as UCB0599 can slow the progression of Parkinson’s disease and whether it is efficacious and well tolerated (which means …

motor symptoms
hoehn and yahr scale
resting tremor
  • 11 Nov, 2022
  • 116 locations
Featured trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma (TIDE-asthma)  

(per participant) will be up to approximately 76 weeks for participants not going into LTS study and will be up to approximately 64 weeks for participants going into LTS study. The randomized

  • 17 Nov, 2022
  • 5 locations
Featured trial
Safety and Efficacy of TSHA-102 in Adult Females With Rett Syndrome (REVEAL Adult Study)

, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is estimated to be up to 63 months.

  • 17 Nov, 2022
  • 1 location